Arbutus Biopharma Corporation (ABUS) has a MoatMap StockRank of 22/100 based on Quality (30/100), Value (34/100), and Momentum (49/100) factor scores. The current signal is SELL. Arbutus Biopharma Corporation is a US healthcare (biopharma) company. Biopharma companies typically involve high R&D, uncertain commercialization, and often do not fit the 'asset-light, high ROIC, durable moat' profile. There's no clear, unpriced macro tailwind that would create an asymmetric opportunity for this specific biotech firm.